Imran is the founding partner at Action Potential Venture Capital, GSK’s corporate venture capital fund focused on investing in companies that pioneer bioelectronic medicines and their enabling technologies. Imran represents Action Potential as a board member in NeuSpera Medical, SetPoint Medical, Presidio Medical and Qionics. Prior to his role at Action Potential, Imran headed up GSK’s Investment Management group and was responsible for accessing technology and innovation external to GSK by making and managing investments in life science venture capital funds as limited partners and direct investments in biotechs. Imran has been with GSK for over 12 years, primarily in various business development functions leading and participating in in-licenses, out-licenses, research collaborations, co-development and co-promotion arrangements, equity investments, and M&A deals. Imran has trained as a Canadian Chartered Accountant and is based in Boston, MA.
